Market open
Sangamo Therapeutics/$SGMO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Sangamo Therapeutics
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
Ticker
$SGMO
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
405
Website
SGMO Metrics
BasicAdvanced
$207M
-
-$0.70
1.10
-
Price and volume
Market cap
$207M
Beta
1.1
52-week high
$2.84
52-week low
$0.30
Average daily volume
3.9M
Financial strength
Current ratio
1.347
Quick ratio
1.151
Long term debt to equity
70.851
Total debt to equity
70.851
Management effectiveness
Return on assets (TTM)
-46.35%
Return on equity (TTM)
-154.94%
Valuation
Price to revenue (TTM)
3.671
Price to book
5.29
Price to tangible book (TTM)
5.29
Price to free cash flow (TTM)
-1.639
Growth
Revenue change (TTM)
-74.04%
Earnings per share change (TTM)
-52.34%
3-year revenue growth (CAGR)
-21.60%
3-year earnings per share growth (CAGR)
-18.01%
What the Analysts think about SGMO
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Sangamo Therapeutics stock.
SGMO Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
SGMO Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
SGMO News
AllArticlesVideos
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile
Business Wire·1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO
Accesswire·1 month ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMO
Accesswire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Sangamo Therapeutics stock?
Sangamo Therapeutics (SGMO) has a market cap of $207M as of March 12, 2025.
What is the P/E ratio for Sangamo Therapeutics stock?
The price to earnings (P/E) ratio for Sangamo Therapeutics (SGMO) stock is 0 as of March 12, 2025.
Does Sangamo Therapeutics stock pay dividends?
No, Sangamo Therapeutics (SGMO) stock does not pay dividends to its shareholders as of March 12, 2025.
When is the next Sangamo Therapeutics dividend payment date?
Sangamo Therapeutics (SGMO) stock does not pay dividends to its shareholders.
What is the beta indicator for Sangamo Therapeutics?
Sangamo Therapeutics (SGMO) has a beta rating of 1.1. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.